Concerns about Spain and Italy renew capital markets’ rejection of area debt. (Reuters) Best Buy (NYSE: BBY) will have to bring in an outsider to change the company’s old philosophy. (Reuters) The…
Canadian-based drug company Cardiome Pharma Corp. (NASDAQ: CRME) announced this morning that Merck & Co. Inc. (NYSE: MRK) has cancelled further development of an oral version of a Cardiome drug being reviewed…
Paul Ausick Drug maker Merck & Co. Inc. (NYSE: MRK) this morning lowered its first quarter non-GAAP EPS estimate to $0.95-$0.98, well below the previous consensus estimate of $1.03. For the full-year, Merck expects…
Paul Ausick Drug maker Merck & Co. Inc. (NYSE: MRK) has released results of a phase III study of its investigational allergy immunotherapy tablet (AIT) for ragweed pollen this morning. According to the company’s…
Paul Ausick The FDA announced today that the use of statins, common among people with high cholesterol, pose problems which were not mentioned on the lables on the drugs before. The agency reported that…
The Pharmaceutical Research and Manufacturers of America (PhRMA) has spoken out against the new 2013 budget proposed by President Obama. PhRMA represents leading pharmaceutical research and biotechnology companies and some of the…
Drug giant Merck & Co. (NYSE: MRK) plans to file this year with the US FDA for approval of the company’s newest sleep aid drug, suvorexant. The drug has completed late-stage trials…
Paul Ausick All three major US stock indexes opened higher this morning, and spent the rest of the day bouncing around the neutral line. The reports from retailers on same-store sales in January were…
Merck & Company, Inc. (NYSE: MRK) is trading up after its earnings report. With a high dividend yield of 4.4%, many investors are watching this despite a stance of little to no…
Jon C. Ogg Earnings season is still upon us. There are going to be many big earnings reports Thursday and we would consider Thursday as the climax for the companies reporting their normal fourth quarter…
Pfizer, Inc. (NYSE: PFE) looks good on the surface on its earnings report for the fourth quarter, but the company’s guidance may be getting in the way a bit. The drug giant…
Jim Cramer has touted several DJIA upside calls in 2012, but on Monday’s MAD MONEY on CNBC Cramer touted Merck & Company, Inc. (NYSE: MRK) as the great pharma outfit with what may…
The tide of patent expirations that is washing over big pharmaceutical houses is cresting now and investors have begun looking forward to how these companies will deal with some sharp blows to…
Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) has been on fire due to the rapid interest of hepatitis C treatments and the bidding of players in the sector. With Merck & Co. (NYSE: MRK) driving further…
US markets opened up slightly this morning and have maintained a slight positive tone for most of the day. Today marks the unofficial beginning of another earnings season, with Alcoa kicking things…
